South San Francisco, United States
Cytokinetics, founded in 1998, is a pioneering biopharmaceutical company headquartered in the United States. The company is at the forefront of muscle performance treatment, specializing in the discovery, development, and commercialization of first-in-class muscle activators and next-in-class muscle inhibitors aimed at debilitating diseases. This innovation is encapsulated in their slogan: "Empowering Muscle Empowering Lives".
As an established leader in muscle biology, Cytokinetics focuses on creating small molecule drug candidates to enhance muscle function and contractility. This strategic focus positions them uniquely within the Biopharma, Biotechnology, and Health Care sectors.
Recently, they secured a significant $550.00M Post-IPO Equity investment on 22 May 2024 from Royalty Pharma, underscoring strong investor confidence. Notably, Cytokinetics has been recognized for its work culture, being named a Great Place to Work-Certified company and part of various prestigious workplace rankings in 2022.
